Show simple item record

dc.contributor.authorThomas, Stephen J.
dc.contributor.authorAgulto, Liane
dc.contributor.authorEdelman, Robert
dc.creatorThomas, S.
dc.date.accessioned2019-07-03T19:29:10Z
dc.date.available2019-07-03T19:29:10Z
dc.date.issued2018-10-01
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054466182&origin=inward
dc.identifier.urihttp://hdl.handle.net/10713/9857
dc.description.abstractDengue virus infections are a major cause of febrile illness that significantly affects individual and societal productivity and drives up health care costs principally in the developing world. Two dengue vaccine candidates are in advanced clinical efficacy trials in Latin America and Asia, and another has been licensed in more than fifteen countries but its uptake has been limited. Despite these advances, standardized metrics for comparability of protective efficacy between dengue vaccines remain poorly defined. The Dengue Illness Index (DII) is a tool that we developed thru refinement of previous similar iterations in an attempt to improve and standardize the measurement of vaccine and drug efficacy in reducing moderate dengue illness. The tool is designed to capture an individual's overall disease experience based on how the totality of their symptoms impacts their general wellness and daily functionality. We applied the DII to a diary card, the Dengue Illness Card (DIC), which was examined and further developed by a working group. The card was then refined with feedback garnered from a Delphi methodology-based query that addressed the adequacy and applicability of the tool in clinical dengue research. There was overall agreement that the tool would generate useful data and provide an alternative perspective to the assessment of drug or vaccine candidates, which in the case of vaccines, are assessed by their reduction in any virologically confirmed dengue of any severity with a focus on the more severe. The DIC needs to be evaluated in the field in the context of vaccine or drug trials, prospective cohort studies, or during experimental human infection studies. Here, we present the final DIC resulting from the Delphi process and offer its further development or use to the dengue research community.en_US
dc.description.urihttps://doi.org/10.1371/journal.pntd.0006593en_US
dc.language.isoen_USen_US
dc.publisherPLOS Oneen_US
dc.relation.ispartofPLoS neglected tropical diseasesen_US
dc.subject.meshDengueen_US
dc.subject.meshDrug Evaluation, Preclinicalen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshSeverity of Illness Indexen_US
dc.titleDengue illness index-A tool to characterize the subjective dengue illness experienceen_US
dc.typeArticleen_US
dc.identifier.doi10.1371/journal.pntd.0006593
dc.identifier.pmid30286086
dc.relation.volume12


This item appears in the following Collection(s)

Show simple item record